Kestra Advisory Services LLC increased its position in Natera, Inc. (NASDAQ:NTRA – Free Report) by 32.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 12,748 shares of the medical research company’s stock after purchasing an additional 3,152 shares during the period. Kestra Advisory Services LLC’s holdings in Natera were worth $5,269,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in NTRA. BlackRock Inc. acquired a new stake in Natera during the 2nd quarter worth $2,962,770,000. Arrowstreet Capital Limited Partnership increased its stake in Natera by 1.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after purchasing an additional 11,793 shares during the period. Maverick Capital Ltd. increased its stake in Natera by 24.1% in the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock valued at $234,315,000 after purchasing an additional 227,605 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Natera by 10.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock valued at $226,220,000 after buying an additional 80,440 shares during the last quarter. Finally, Bank of America Corp DE purchased a new stake in shares of Natera in the second quarter valued at about $199,960,000. 99.90% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities analysts recently issued reports on NTRA shares. Robert W. Baird dropped their price target on Natera from $458.00 to $403.00 and set an “outperform” rating on the stock in a research report on Monday. Canaccord Genuity Group increased their price objective on Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. Royal Bank Of Canada increased their price objective on Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Piper Sandler reiterated an “overweight” rating and issued a $363.50 target price on shares of Natera in a research note on Friday, November 6th. Finally, UBS Group boosted their target price on Natera from $290.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $394.31.
View Our Latest Research Report on NTRA
Insider Transactions at Natera
In other news, insider Solomon Moshkevich sold 3,419 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $409.77, for a total value of $1,401,003.63. Following the completion of the transaction, the insider owned 101,323 shares in the company, valued at $41,519,125.71. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 302 shares of Natera stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $400.01, for a total value of $120,803.02. Following the transaction, the insider directly owned 195,276 shares of the company’s stock, valued at $78,112,352.76. This trade represents a 0.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 47,056 shares of company stock valued at $17,760,989 in the last three months. 5.05% of the stock is owned by company insiders.
Natera Trading Up 1.0%
NTRA stock opened at $322.94 on Friday. The firm has a 50 day moving average of $379.87 and a 200-day moving average of $271.22. Natera, Inc. has a 12-month low of $181.00 and a 12-month high of $437.41.
Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Natera had a negative return on equity of 8.61% and a negative net margin of 5.66%. The firm had revenue of $793.98 million during the quarter, compared to analyst estimates of $707.54 million. During the same quarter in the prior year, the company earned ($0.64) EPS. The business’s revenue was up 34.1% on a year-over-year basis. Sell-side analysts forecast that Natera, Inc. will post -1.25 earnings per share for the current fiscal year.
About Natera
Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.
See Also
- Five stocks we like better than Natera
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
